BRPI0705590A2 - uso de composição farmacêutica contendo crotoxina para o tratamento de distonias musculares - Google Patents

uso de composição farmacêutica contendo crotoxina para o tratamento de distonias musculares

Info

Publication number
BRPI0705590A2
BRPI0705590A2 BRPI0705590-0A BRPI0705590A BRPI0705590A2 BR PI0705590 A2 BRPI0705590 A2 BR PI0705590A2 BR PI0705590 A BRPI0705590 A BR PI0705590A BR PI0705590 A2 BRPI0705590 A2 BR PI0705590A2
Authority
BR
Brazil
Prior art keywords
crotoxin
pharmaceutical composition
muscular
treatment
dystonias
Prior art date
Application number
BRPI0705590-0A
Other languages
English (en)
Inventor
Barros Ribeiro Geraldo De
De Almeida Henderson Celestino
Velarde David Toledo
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0705590-0A priority Critical patent/BRPI0705590B1/pt
Priority to PCT/BR2008/000307 priority patent/WO2009018643A2/en
Publication of BRPI0705590A2 publication Critical patent/BRPI0705590A2/pt
Publication of BRPI0705590B1 publication Critical patent/BRPI0705590B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

USO DE COMPOSIçãO FARMACêUTICA CONTENDO CROTOXINA PARA O TRATAMENTO DE DISTONIAS MUSCULARES. A presente invenção diz respeito ao uso de uma composição farmacêutica que contém uma toxina, extraída do veneno da cascavel Crotalus durissus terrificus, conhecida como crotoxina, capaz de atuar como agente que promove a paralisia muscular. Nesta invenção são descritos ainda usos médicos da formulação desenvolvida em condições patológicas nas quais se deseja alcançar uma paralisia muscular, tais como os estrabismos, biefaroespasmos, nistagmo, entre outras.
BRPI0705590-0A 2007-08-07 2007-08-07 Uso de composição farmacêutica contendo crotoxina para o tratamento de distonias musculares BRPI0705590B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRPI0705590-0A BRPI0705590B1 (pt) 2007-08-07 2007-08-07 Uso de composição farmacêutica contendo crotoxina para o tratamento de distonias musculares
PCT/BR2008/000307 WO2009018643A2 (en) 2007-08-07 2008-08-06 Use of pharmaceutical compound containing crotoxin for the treatment of muscle dystonias

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0705590-0A BRPI0705590B1 (pt) 2007-08-07 2007-08-07 Uso de composição farmacêutica contendo crotoxina para o tratamento de distonias musculares

Publications (2)

Publication Number Publication Date
BRPI0705590A2 true BRPI0705590A2 (pt) 2009-03-24
BRPI0705590B1 BRPI0705590B1 (pt) 2021-06-29

Family

ID=40341798

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0705590-0A BRPI0705590B1 (pt) 2007-08-07 2007-08-07 Uso de composição farmacêutica contendo crotoxina para o tratamento de distonias musculares

Country Status (2)

Country Link
BR (1) BRPI0705590B1 (pt)
WO (1) WO2009018643A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2762951T3 (es) * 2015-04-24 2020-05-26 Consiglio Nazionale Ricerche Nuevo uso terapéutico de la neurotoxina botulínica serotipo A
RU2761267C1 (ru) * 2021-06-18 2021-12-06 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ имени Гельмгольца" Минздрава России) Способ комплексного лечения нистагма

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1391207A1 (en) * 2001-04-24 2004-02-25 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic

Also Published As

Publication number Publication date
WO2009018643A2 (en) 2009-02-12
WO2009018643A3 (en) 2009-03-26
BRPI0705590B1 (pt) 2021-06-29

Similar Documents

Publication Publication Date Title
Manini et al. Myogenic and proteolytic mRNA expression following blood flow restricted exercise
BR112017024777A2 (pt) uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados?
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
GT200600045A (es) Derivados de piridizina y su uso como agentes terapeuticos
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BR112015020819A2 (pt) uso de faecalibacterium prausnitzii htf-f (dsm 26943) para supressão de inflamação
BR112018008684A2 (pt) formulações de toxina botulínica injetáveis e processos de uso das mesmas com longa duração do efeito terapêutico ou cosmético
BR112012014180A2 (pt) composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA200802204A1 (ru) Применение ингибиторов dpp iv
EA201300550A1 (ru) Фармацевтическая композиция, способы лечения и их применение
NO20085056L (no) Insulinderivat
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
BR112012022211A2 (pt) composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto
WO2007061554A3 (en) Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
BR112012006010A2 (pt) composto de glicina
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
BR112018002416A2 (pt) derivados de insulina e seus usos médicos
BRPI0911650B8 (pt) peptídeo tendo uma atividade de um fator de crescimento (gf) e derivado de gf e composição farmacêutica para aperfeiçoamento de uma condição de pele e para o tratamento de um ferimento
BR112012009432A8 (pt) Anticorpo anti-hsv e composição farmacêutica que o compreende
CR20110226A (es) Composición para tratar enfermedad
BR112012017300A2 (pt) processo de para preparação de uma biomassa compreendendo plantaricina e usos da mesma no campo médico

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B12C Appeal against dismissal [chapter 12.3 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR/MG) , FUNDACAO EZEQUIEL DIAS - FUNED (BR/MG)

Owner name: UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR/MG) , FUN

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06V Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/08/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2734 DE 30-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.